Skip to content
Research/Hormone Optimization/Testosterone Undecanoate

Testosterone Undecanoate

Aveed, Jatenzo. Ultra-long-acting testosterone ester. FDA-approved as Aveed (IM, every 10 weeks) and Jatenzo (oral). Brand names: Aveed, Jatenzo.

Intelligence Profile

Research Papers

Key Research Papers and Clinical Trials

Recent research on testosterone undecanoate has explored its applications across several clinical areas, though specific study details and sample sizes are not available from the provided evidence.

Clinical Applications and Safety

A 2026 study examined how testosterone therapy may influence the relationship between age and mortality in men with adult-onset testosterone deficiency, suggesting potential survival benefits. However, safety concerns have also emerged, including a case report documenting cerebral venous sinus thrombosis in a transgender patient using testosterone for gender-affirming therapy, highlighting the need for careful monitoring.

Pediatric and Adolescent Use

Multiple studies have investigated testosterone undecanoate in younger populations. Research has examined testosterone therapy in boys with constitutional delay of growth and puberty through systematic review and meta-analysis approaches. Additionally, studies have shown that low-dose testosterone treatment can improve wellbeing and emotional state in boys with self-limited delayed puberty.

Specialized Medical Conditions

Clinical research has expanded into specific medical contexts, including a randomized controlled trial examining testosterone-augmented multimodal exercise interventions in spinal cord injury patients. Another study investigated testosterone supplementation combined with nutrition and exercise for muscle mass improvement in men with cirrhosis.

Clinical Trial Development

The clinical trial landscape includes several completed and ongoing studies. Notable trials include a completed Phase 3 study evaluating efficacy and safety of oral testosterone undecanoate in hypogonadal men (NCT03198728), and completed Phase 2 pharmacokinetic studies examining oral testosterone formulations and time to steady-state (NCT02697188, NCT00911586). Currently, a Phase 2 trial is recruiting participants to study locomotor training with testosterone for bone and muscle health after spinal cord injury (NCT04460872).

Research Methods

Recent work has also focused on detection methods, with research developing urinary proteomic signatures to identify exogenous testosterone exposure following oral testosterone undecanoate administration, which may have applications in clinical monitoring or anti-doping efforts.

The evidence base continues to evolve, though specific study methodologies, sample sizes, and detailed outcomes require direct access to the full research publications for comprehensive evaluation.

Free account required

Research papers requires a free AXIFI account to access clinical data, safety profiles, and research papers.